title: Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis.
abstract: Methotrexate (MTX) is widely utilized for the treatment of patients with rheumatoid arthritis (RA); however, recent observation of the MTX-resistant patients proposed some difficulty in MTX-dependent therapeutic approach for RA. To access cellular events related to MTX resistance in RA in respect to inflammatory bone destruction, we investigated on an involvement of the potent inflammatory mediator adenosine in the regulation of osteoclastogenesis and inflammatory bone destruction. In rats with adjuvant-induced arthritis (AA rats), MTX efficiently suppressed bone destruction when it was administrated within 3 days after adjuvant injection, while it could not suppress inflammatory bone destruction if MTX was injected at the time of onset of inflammation (at day 10 after adjuvant injection). Time-course change in the level of plasma adenosine of AA rats was estimated by use of high-performance liquid chromatography and elucidated that adenosine level was markedly elevated till 10 days after adjuvant injection. In vitro bone marrow culture system for evaluating osteoclastogenesis, MTX markedly suppressed osteoclastogenesis in a stromal cell-dependent manner. This MTX-induced suppression of osteoclastogenesis was abrogated by the addition of adenosine. MTX suppressed the expression of mRNA for the receptor activator NF-κB ligand (RANKL), but it did not suppress the expression of osteoprotegerin (OPG). The addition of MTX and adenosine together markedly suppressed the level of OPG expression. Abolishment of MTX action by adenosine was significantly blocked by MRS1754, a highly selective antagonist for the A(2b) adenosine receptor (A(2b)AR), but not by caffeine, an antagonist for A₁, A(2a), A₃ AR (A₁AR, A(2a)AR, and A₃AR), which suggests that adenosine acts through A(2b)AR. Immunohistochemical studies showed abundant expression of A(2b)AR in cells localized in the bone-bone marrow boundary of the distal tibia in AA rats but not in control rats. When adenosine was injected in the ankle joints of MTX-treated AA rats, the suppressive effects of MTX on bone destruction was abolished. The current data therefore suggest that upregulation of adenosine production abolished the suppressive effect of MTX on osteoclastic bone destruction. Involvement of the adenosine-A(2b)AR system may explain MTX resistance in RA.
authors.affiliation: Department of Molecular Cell Biology and Oral Anatomy, Kyushu University, Fukuoka, Japan.
authors.forename: Junpei
authors.initials: J
authors.lastname: Teramachi
authors.forename: Akiko
authors.initials: A
authors.lastname: Kukita
authors.forename: Yin-Ji
authors.initials: YJ
authors.lastname: Li
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ushijima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohkuma
authors.forename: Naohisa
authors.initials: N
authors.lastname: Wada
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Seiji
authors.initials: S
authors.lastname: Nakamura
authors.forename: Toshio
authors.initials: T
authors.lastname: Kukita
mesh_terms: D000241:Adenosine / Q000097:blood / Q000502:physiology*; D000818:Animals; D018501:Antirheumatic Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000473:pathology; D001483:Base Sequence; D001842:Bone and Bones / Q000473:pathology*; D002851:Chromatography, High Pressure Liquid; D017931:DNA Primers; D007150:Immunohistochemistry; D008727:Methotrexate / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism; D053245:RANK Ligand / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018501:Antirheumatic Agents; D017931:DNA Primers; D053244:Osteoprotegerin; D053245:RANK Ligand; D000241:Adenosine; D008727:Methotrexate